ATHE Stock Overview
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Alterity Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.17 |
| 52 Week High | AU$5.41 |
| 52 Week Low | AU$1.01 |
| Beta | 0.68 |
| 11 Month Change | -18.18% |
| 3 Month Change | -16.43% |
| 1 Year Change | -51.25% |
| 33 Year Change | -90.33% |
| 5 Year Change | -88.70% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK
Aug 25Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy
Jul 06Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology
Sep 16Alterity Therapeutics names Dr. David Stamler as CEO
Jan 07Alterity and UniQuest partner to reverse bacterial resistance to antibiotics
Dec 21Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders
Nov 16Shareholder Returns
| ATHE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.9% | -0.6% | -1.3% |
| 1Y | -51.2% | 19.8% | 30.7% |
Return vs Industry: ATHE underperformed the US Biotechs industry which returned 19.1% over the past year.
Return vs Market: ATHE underperformed the US Market which returned 30.1% over the past year.
Price Volatility
| ATHE volatility | |
|---|---|
| ATHE Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ATHE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ATHE's weekly volatility has decreased from 25% to 10% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 10 | David Stamler | alteritytherapeutics.com |
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.
Alterity Therapeutics Limited Fundamentals Summary
| ATHE fundamental statistics | |
|---|---|
| Market cap | US$10.46m |
| Earnings (TTM) | -US$12.54m |
| Revenue (TTM) | US$2.63m |
4.0x
P/S Ratio-0.8x
P/E RatioIs ATHE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATHE income statement (TTM) | |
|---|---|
| Revenue | AU$4.02m |
| Cost of Revenue | AU$214.30k |
| Gross Profit | AU$3.80m |
| Other Expenses | AU$22.93m |
| Earnings | -AU$19.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0036 |
| Gross Margin | 94.67% |
| Net Profit Margin | -475.79% |
| Debt/Equity Ratio | 0% |
How did ATHE perform over the long term?
See historical performance and comparison